Fusion Antibodies plc

Equities

FAB

GB00BDQZGK16

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:18 2024-06-07 EDT			5-day change	1st Jan Change
3.4 ^GBX	0.00%		-9.33%	-20.00%

05-23	Celadon ships to US; Oxford BioDynamics-Goodbody pact	AN
05-23	Fusion Antibodies plc Announces New Contract with Existing Client Project to Develop Therapeutic	CI

Fusion Antibodies plc Provides Revenue Guidance for the Year Ended March 31, 2020 and First Quarter Ended June 2020

July 06, 2020 at 02:00 am

Fusion Antibodies plc provided revenue guidance for the year ended March 31, 2020 and first quarter ended June 2020. The Company now expects to report revenues for the year to 31 March 2020 of c. £3.9 million, being a 79% increase on the prior year (fiscal year 2019: £2.2 million). Revenue for the quarter to June 2020 of approximately £0.975 million.

Latest news about Fusion Antibodies plc

Celadon ships to US; Oxford BioDynamics-Goodbody pact	05-23	AN
Fusion Antibodies plc Announces New Contract with Existing Client Project to Develop Therapeutic	05-23	CI
EARNINGS AND TRADING: Software Circle & Beximco report higher revenue	04-30	AN
Fusion Antibodies inks commercial contract for OptiPhage library	04-15	AN
Fusion Antibodies Secures Contract to Set Up OptiPhage Library	04-15	MT
Fusion Antibodies plc Enters into Commercial Contract to Develop a Bespoke OptiPhageTM Library	04-15	CI
Sondrel wins USD23 million contract	02-27	AN
Fusion Antibodies Lands Antibodies Contract with Diagnostics Company	02-27	MT
Fusion Antibodies plc Receives First Purchase Order Under the Master Services Agreement	02-27	CI
Fusion Antibodies raises GBP1.4 million via placing	02-14	AN
Fusion Antibodies Raises GBP1 Million via Share Issue	02-14	MT
Fusion Antibodies strikes follow-on research and development project	02-06	AN
Fusion Antibodies Receives Follow-On Project from US Biotechnology Client	02-06	MT
AIM WINNERS & LOSERS: Beeks Financial Cloud is ahead of expectations	02-06	AN
Fusion Antibodies plc Receives Follow-On Project Award and R&D Update	02-06	CI
Fusion Antibodies gets tax credit from UK HMRC for OptiMAL platform	02-01	AN
Fusion Antibodies Receives R&D Tax Credit from UK Government	02-01	MT
FTSE 100 slips as miners hold down index	12-04	AN
Fusion Antibodies shares fall with revenue despite "positive" outlook	12-04	AN
AIM WINNERS & LOSERS: Cornerstone FS to beat 2023 expectations	12-04	AN
Fusion Antibodies plc Reports Earnings Results for the Half Year Ended September 30, 2023	12-04	CI
Fusion Antibodies plc Provides Revenue Guidance for the Fiscal Year 2024	12-04	CI
Fusion Antibodies Shares Rise on US Cancer Institute Collaboration	11-28	DJ
Fusion Antibodies shares up on deal with US National Cancer Institute	11-28	AN
AIM WINNERS & LOSERS: Totally swings to half-year loss on NHS blow	11-28	AN

Chart Fusion Antibodies plc

Duration

Period

More charts

Company Profile

Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The principal activity of the Company is the research, development, and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. It is engaged in providing an integrated end-to-end range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. It offers a range of services in antibody generation, development, characterization, optimization, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanization using its proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for use downstream by the customer to produce material for clinical trials. It is also developing OptiMAL, a mammalian antibody library and discovery platform yielding fully human antibodies.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FUSION ANTIBODIES PLC	-20.00%	4.13M
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research